(PharmaNewsWire.Com, November 19, 2017 ) Overview of Atopic Dermatitis (AD) Market:
The “Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecast – 2025” research report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Atopic Dermatitis from 2017 to 2025 segmented by seven major markets. In addition, the forecasted epidemiology of Atopic Dermatitis till 2025 is also provided. This report also covers market drivers, market barriers and unmet medical need.
United States contributes the major share of Atopic Dermatitis market as compared to EU5 countries and Japan. The therapeutic market of Atopic Dermatitis in 7MM is expected to grow with healthy CAGR value from 2015 - 2025.
Market is driven by various approved drugs for Atopic Dermatitis such as Elidel (Novartis), Protopic (Fujisawa Healthcare) and Desonate (Bayer Healthcare). There has been a positive impact on the market with the approval of Eucrisa (Pfizer) and Dupilumab (Regeneron Pharmaceuticals / Sanofi) in 2016 and 2017 respectively.
‘Atopic Dermatitis - Market Insights, Epidemiology and Market Forecast-2025’ report provides an overview of epidemiology and market trends of Atopic Dermatitis for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
A complete analysis of the competitive landscape of the Global Atopic Dermatitis (AD) Market is provided in the report. This section includes company profiles of market key players. The profiles include contact information, gross, capacity, product details of each firm, price and cost. This report investigates new project feasibility with a purpose of enlightening new entrants about the possibilities in this market. In this report, thorough SWOT analysis & investment analysis is provided which forecasts imminent opportunities for the Atopic Dermatitis (AD) Market players.
Key Coverage and Benefits: 1. The report will help in developing business strategies by understanding the trends shaping and driving the Atopic Dermatitis market. 2. The Report provides detailed historical and forecasted epidemiological data of Atopic Dermatitis in the 7MM i.e., United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025. 3. Organize sales and marketing efforts by identifying the best opportunities for Atopic Dermatitis in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan. 4. To understand the future market competition in the Atopic Dermatitis market and insightful review of the key market drivers and barriers. 5. To understand the regulatory scenario in major markets. 6. The Report covers the detailed historical and forecasted Atopic Dermatitis market covering the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Major Points in Table of Contents:
Global Atopic Dermatitis (AD) Market Report 2017 1. Report Introduction 2. Atopic Dermatitis Market Overview at a Glance 3. Disease Background and Overview 4. Epidemiology and Patient Population 5. Treatment Practices 6. Treatment Algorithm 7. Treatment Failure 8. Treatment by class 9. Emerging Therapies 10. Nemolizumab: Galderma Pharma 11. Tralokinumab: LEO Pharma 12. Tradipitant: Vanda Pharmaceuticals 13. ZPL-389: Novartis 14. NST-141: Nippon Shinyaku 15. Serlopitant: Menlo Therapeutics 16. DS107: DS Biopharma 17. Asimadoline: Tioga Pharmaceuticals 18. GSK2894512: GlaxoSmithKline 19. Lebrikizumab: Roche 20. DMT210: Dermata Therapeutics 21. SNA-120: Sienna Biopharmaceutical 22. RVT-501: Roivant Sciences 23. OPA-15406: Otsuka Pharmaceutical 24. Current Unmet Need 25. Atopic Dermatitis: Market Analysis 26. Atopic Dermatitis: United States Market Outlook 27. Atopic Dermatitis: EU5 28. Market Outlook 29. Atopic Dermatitis: Japan Market Outlook 30. Market Drivers 31. Market Barriers 32. Expert Opinions 33. Appendix
About us: Precise market reports, a one-stop research platform designed to help key decision makers and dynamic thought leaders across various industry verticals worldwide by making them aware of the past, current and future market scenario. Tier 1's, SME's startups, top management consultants, have clearly visualized their environment using our analysis, thus enabling them to make critical business decisions and in devising a strategic plan.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
